Moderna to Report Third Quarter Financial Results on Thursday, November 4, 2021
October 14 2021 - 8:00AM
Business Wire
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today announced
that it will host a live conference call and webcast at 8:00 a.m.
ET on Thursday, November 4, 2021 to report its third quarter 2021
financial results, and provide a corporate update.
To access the live conference call, please dial 866-922-5184
(domestic) or 409-937-8950 (international) and refer to conference
ID 9177025. A webcast of the call will also be available under
“Events and Presentations” in the Investors section of the Moderna
website at investors.modernatx.com. The archived webcast will be
available on Moderna’s website approximately two hours after the
conference call and will be available for one year following the
call.
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across six modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for both clinical and commercial production at
scale and at unprecedented speed. Moderna maintains alliances with
a broad range of domestic and overseas government and commercial
collaborators, which has allowed for the pursuit of both
groundbreaking science and rapid scaling of manufacturing. Most
recently, Moderna’s capabilities have come together to allow the
authorized use of one of the earliest and most-effective vaccines
against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and autoimmune diseases. Moderna has been named a top
biopharmaceutical employer by Science for the past six years. To
learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211014005274/en/
Investors: Lavina Talukdar Senior Vice President &
Head of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From May 2023 to May 2024